ShannonMaudeMD

PubMed

• Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review.
  Connor B Grady, Yimei Li, Shannon L Maude, Elizabeth O Hexner, Noelle V Frey
  Transplantation and Cellular Therapy. 2024-11-26
• TET2 regulates early and late transitions in exhausted CD8T cell differentiation and limits CAR T cell function.
  Alexander J Dimitri, Amy E Baxter, Gregory M Chen, Caitlin R Hopkins, Geoffrey T Rouin
  Science Advances. 2024-11-15
• 2 citations
  Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents.
  Caroline Diorio, Laura Hernandez-Miyares, Diego A Espinoza, Brenda L Banwell, Amit Bar-Or
  Blood. 2024-09-26

Journal Articles

• Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell  
  Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature

Abstracts/Posters

• Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes 
  60th American Society of Hematology Annual Meeting - 11/30/2018